FDA has expanded the approval of aflibercept (Eylea, Regeneron) injection to treat diabetic retinopathy in patients with macular edema.
FDA has expanded the approval of aflibercept (Eylea, Regeneron) injection to treat diabetic retinopathy in patients with macular edema.
Diabetic retinopathy (DR) is a disorder of the retinal vasculature that occurs in patients with long-standing diabetes. Diabetic retinopathy is the most common diabetic eye disease and a leading cause of blindness in American adults. Ocular neovascularization, or the growth of new abnormal blood vessels on the surface of the retina, may occur in some cases of DR in patients with diabetic macular edema (DME) which can cause vision loss and eventual blindness.
Related:FDA approves Lucentis for treatment of diabetic retinopathy in people with DME
Elyea is a recombinant fusion protein that acts as a decoy receptor that binds vascular endothelial growth factor- A (VEGF-A) and placental growth factor (PIGF) to prevent binding and activation of their respective receptors. VEGF-A and PIGF are members of the VEGF family of angiogenic factors that play an important role in the permeability and growth of new blood vessels. Inhibiting the binding of VEGF-A and PIGF to their receptors suppresses neovascularization in the eye and slows vision loss.
Read more: FDA drug approvals
Eylea is administered by a trained physician as an injection into the eye once a month for the first 5 injections and then once every 2 months. It is intended to be used along with appropriate interventions to control blood pressure, cholesterol and blood glucose.
"Diabetic retinopathy coupled with DME is a serious complication of diabetes that can threaten the vision of many working-age adults," said George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories. "In addition to improving visual acuity in people with DME,Eylea also improves these patients' retinal vessel damage, or retinopathy. Eylea is the only treatment option for diabetic retinopathy in patients with DME that is approved for less than monthly dosing after an initial monthly dosing period."
The expanded approval of Eylea is based on 2 clinical trials with 679 participants in which patients were randomly assigned to receive Eylea or macular laser photocoagulation, a laser-based treatment used to burn small areas of the retina. Results showed that participants treated with Eylea showed significant improvement in the severity of their DR compare to the laser-treated group.
Eylea was previously approved to treat wet (neovascular) age-related macular degeneration as well as for the treatment of DME and macular edema secondary to retinal vein occlusions. The most common side effects associated with the use of Eylea include bleeding of the conjunctiva, eye pain, cataracts, floaters, increased intraocular pressure, and vitreous detachment.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More